Constellation Energy Corp (CEG)vsGlaxoSmithKline PLC ADR (GSK)
CEG
Constellation Energy Corp
$303.32
+2.87%
UTILITIES · Cap: $106.82B
GSK
GlaxoSmithKline PLC ADR
$54.71
+3.32%
HEALTHCARE · Cap: $104.12B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 28% more annual revenue ($32.67B vs $25.53B). GSK leads profitability with a 17.5% profit margin vs 9.1%. GSK appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 70/100 (B).
CEG
Hold43
out of 100
Grade: D
GSK
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-441.4%
Fair Value
$51.14
Current Price
$303.32
$252.18 premium
Margin of Safety
+66.0%
Fair Value
$172.22
Current Price
$54.71
$117.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Every $100 of equity generates 43 in profit
Earnings expanding 54.7% YoY
Large-cap with strong market position
Attractively priced relative to earnings
Generating 1.5B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 48.9%
Negative free cash flow — burning cash
Trading at 10.1x book value
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : CEG
The strongest argument for CEG centers on Market Cap. Revenue growth of 12.9% demonstrates continued momentum.
Bull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, EPS Growth. Profitability is solid with margins at 17.5% and operating margin at 18.9%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : CEG
The primary concerns for CEG are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : GSK
The primary concerns for GSK are Price/Book, Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
CEG profiles as a value stock while GSK is a mature play — different risk/reward profiles.
CEG carries more volatility with a beta of 1.11 — expect wider price swings.
CEG is growing revenue faster at 12.9% — sustainability is the question.
GSK generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
GSK scores higher overall (70/100 vs 43/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Constellation Energy Corp
UTILITIES · UTILITIES - INDEPENDENT POWER PRODUCERS · USA
Constellation Energy Corporation is an energy producer in the United States. The company is headquartered in Baltimore, Maryland.
Visit Website →GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other UTILITIES - INDEPENDENT POWER PRODUCERS Stocks
Want to dig deeper into these stocks?